RSV Shot Shortage Sparks Concerns and Frustration Among Pediatricians

Pediatricians are expressing frustration and concern over persistent shortages of nirsevimab, a monoclonal antibody shot that was hailed as a game-changer in preventing respiratory syncytial virus (RSV) in infants. The Centers for Disease Control and Prevention (CDC) predicts a bad RSV season this year, and the shortage of the drug has led to the CDC stepping in to help distribute doses. Doctors report turning away parents seeking the shot for their babies, and some hospitals are prioritizing shots for vulnerable infants, despite supply constraints. The manufacturer, Sanofi, cites unprecedented demand as the cause of the shortage. Transparency from the manufacturer has been an issue, hindering equitable allocation planning. Short-term solutions are being implemented, but gaps in access to the drug remain.